Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer

1. García-Carbonero, R.
2. Van Cutsem, E.
3. Rivera, F.
4. Jassem, J.
5. Gore, I.
6. Tebbutt, N.
7. Braiteh, F.
8. Argiles, G.
9. Wainberg, Z.A.
10. Funke, R.
11. Anderson, M.
12. McCall, B.
13. Stroh, M.
14. Wakshull, E.
15. Hegde, P.
16. Ye, W.
17. Chen, D.
18. Chang, I.
19. Rhee, I.
20. Hurwitz, H.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1634/THEONCOLOGIST.2016-0133 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus